BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study
Khaled Awad, Raul Weiss, Asim Yunus, Jon M Bittrick, Rajasekhar Nekkanti, Mahmoud Houmsse, Toshimasa Okabe, Teagan Adamson, Crystal Miller, Abdul K Alawwa, Khaled Awad, Raul Weiss, Asim Yunus, Jon M Bittrick, Rajasekhar Nekkanti, Mahmoud Houmsse, Toshimasa Okabe, Teagan Adamson, Crystal Miller, Abdul K Alawwa
Abstract
Background: Insertable cardiac monitors are utilized for the diagnosis of arrhythmias and traditionally have been inserted within hospitals. Recent code updates allow for reimbursement of office-based insertions; however, there is limited information regarding the resources and processes required to support in-office insertions. We sought to determine the safety and feasibility of in-office insertion of the BioMonitor 2 and better understand in-office procedures, including patient selection, pre-insertion protocols, resource availability, and staff support.
Methods: Patients meeting an indication for a rhythm monitor were prospectively enrolled into this single-arm, non-randomized trial. All patients underwent insertion in an office setting. Two follow-up visits at days 7 and 90 were required. Information on adverse events, device performance, office site preparations, and resource utilization were collected.
Results: Eighty-two patients were enrolled at six sites. Insertion was successful in all 77 patients with an attempt. Oral anticoagulation was stopped in 20.8% of patients and continued through insertion in 23.4%, while prophylactic antibiotics were infrequently utilized (37.7% of study participants). On average, the procedure required a surgeon plus two support staff and 35 min in an office room to complete the 8.4 min insertion procedure. The mean R-wave amplitude was 0.77 mV at insertion and 0.67 mV at 90-days with low noise burden (2.7%). There were no procedure related complications. Two adverse events were reported (event rate 2.7% [95% CI 0.3, 9.5%]).
Conclusions: In-office insertion of the BioMonitor 2 is safe and feasible. Devices performed well with high R-wave amplitudes and low noise burden. These results further support shifting cardiac monitor insertions to office-based locations.
Trial registration: clinicaltrials.gov, NCT02756338. Registered 29 April 2016.
Keywords: Adverse event; BioMonitor 2; Feasibility; Insertable cardiac monitor; Office procedure; Safety.
Conflict of interest statement
KA: Consultant honoraria from BIOTRONIK, Inc.; Research support from BioSense Webster. RW: Research support from Boston Scientific, Medtronic, Abbott, BIOTRONIK, Inc., and Biosense Webster; Consultant honoraria from Boston Scientific, BIOTRONIK, Inc., Biosense Webster, and Merit Medical; Advisory board for Boston Scientific and Biosense Webster. AY: Consulting honoraria from BIOTRONIK, Inc.. JMB, RN, MH, and TO: No conflicts of interest to declare. TA and CM: Employed by BIOTRONIK, Inc.. AKA: Consultant honoraria from St. Jude Medical/Abbott, Boston Scientific, and Medtronic; Research support from St. Jude Medical/Abbott, Boston Scientific, and BIOTRONIK, Inc.; Speaking fees from Boston Scientific.
Figures
References
- Kapa S, Epstein AE, Callans DJ, Garcia FC, Lin D, Bala R, et al. Assessing arrhythmia burden after catheter ablation of atrial fibrillation using an implantable loop recorder: the ABACUS study. J Cardiovasc Electrophysiol. 2013;24:875–881. doi: 10.1111/jce.12141.
- Pürerfellner H, Sanders P, Pokushalov E, Di Bacco M, Bergemann T, Dekker LR. Miniaturized reveal LINQ insertable cardiac monitoring system: first-in-human experience. Heart Rhythm. 2015;12:1113–1119. doi: 10.1016/j.hrthm.2015.02.030.
- Harley DH, Collins DR., Jr Patient satisfaction after blepharoplasty performed as office surgery using oral medication with the patient under local anesthesia. Aesthet Plast Surg. 2008;32:77–81. doi: 10.1007/s00266-007-9014-9.
- Hancox JG, Venkat AP, Coldiron B, Feldman SR, Williford PM. The safety of office-based surgery: review of recent literature from several disciplines. Arch Dermatol. 2004;140:1379–1382. doi: 10.1001/archderm.140.11.1379.
- Rogers JD, Sanders P, Piorkowski C, Sohail MR, Anand R, Crossen K, et al. In-office insertion of a miniaturized insertable cardiac monitor: results from the reveal LINQ in-office 2 randomized study. Heart Rhythm. 2017;14:218–224. doi: 10.1016/j.hrthm.2016.11.001.
- Ooi SY, Ng B, Singarayar S, Hellestrand K, Illes P, Mohamed U, et al. BioMonitor 2 pilot study: early experience with implantation of the Biotronik BioMonitor 2 implantable cardiac monitor. Heart Lung Circ. 2018;27:1462–1466. doi: 10.1016/j.hlc.2017.09.005.
- Reinsch N, Ruprecht U, Buchholz J, Diehl RR, Kalsch H, Neven K. The BioMonitor 2 insertable cardiac monitor: clinical experience with a novel implantable cardiac monitor. J Electrocardiol. 2018;51:751–755. doi: 10.1016/j.jelectrocard.2018.05.017.
- Steffel J, Wright DJ, Schäfer H, Rashid-Fadel T, Lewalter T. Insertion of miniaturized cardiac monitors outside the catheter operating room: experience and practical advice. Europace. 2017;19:1624–1629. doi: 10.1093/europace/euw304.
- Zacà V, Marcucci R, Parodi G, Limbruno U, Notarstefano P, Pieragnoli P, et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17:840–854. doi: 10.1093/europace/euu357.
- Mittal S, Sanders P, Pokushalov E, Dekker L, Kereiakes D, Schloss EJ, et al. Safety profile of a miniaturized Insertable cardiac monitor: results from two prospective trials. Pacing Clin Electrophysiol. 2015;38:1464–1469. doi: 10.1111/pace.12752.
- Beinart SC, Natale A, Verma A, Amin A, Kasner S, Diener HC, et al. Real-world use of prophylactic antibiotics in Insertable cardiac monitor procedures. Pacing Clin Electrophysiol. 2016;39:837–842. doi: 10.1111/pace.12886.
- Lacour P, Dang PL, Huemer M, Parwani AS, Attanasio P, Pieske B, et al. Performance of the new BioMonitor 2-AF Insertable cardiac monitoring system: can better be worse? Pacing Clin Electrophysiol. 2017;40:516–526. doi: 10.1111/pace.13059.
- Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121:458–477. doi: 10.1161/CIRCULATIONAHA.109.192665.
- Wong GR, Lau DH, Middeldorp ME, Harrington JA, Stolcman S, Wilson L, et al. Feasibility and safety of reveal LINQ insertion in a sterile procedure room versus electrophysiology laboratory. Int J Cardiol. 2016;223:13–17. doi: 10.1016/j.ijcard.2016.08.113.
- Way JC, Culham BA. Establishment and cost analysis of an office surgical suite. Can J Surg. 1996;39:379–383.
- Duquette S, Nosrati N, Cohen A, Munshi I, Tholpady S. Decreased wait times after institution of office-based hand surgery in a veterans administration setting. JAMA Surg. 2015;150:182–183. doi: 10.1001/jamasurg.2014.1239.
Source: PubMed